COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled CELLS ENGINEERED TO CONTAIN GENES OF INTEREST WITHOUT DRUG RESISTANCE GENE MARKERS AND MATERIALS AND METHODS THEREFOR, the specification of which

Regular Application

was filed on [Date] as Application Serial No. [App. No.].						
PCT Application Entering National Phase						
was filed on [Date] as PCT International Application No. [App. No.] and was amended on [Date of Amendment] (if applicable).						
I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.						
I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56(a).						
I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.						
Prior Foreign Application(s)		į	Priority Clain	ned		
	:	<u> </u>] Yes	□ No		
untry)	(Day/Month/Year Filed)	j				
I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.						
(Filing Date)						
I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.						
(Filing Date)	(Status notanted nandin		1 D			
	PCT Application En PCT International Application and understand the content to above. formation which is material to that also identified below a ton on which priority is claimed to about the content to above. formation which is material to the also identified below a ton on which priority is claimed to about the also identified below a ton on which priority is claimed to also identified below a ton on which priority is claimed to also identified below a ton on which priority is claimed to also identified below a to also ident	PCT Application Entering National Phase PCT International Application No. [App. No.] and was amend and understand the contents of the above-identified specific to above. formation which is material to patentability as defined in Title fits under Title 35, United States Code, § 119(a)-(d) of any for the have also identified below any foreign application for patent on on which priority is claimed. [Day/Month/Year Filed] 35, United States Code, § 119(e) of any United States provision (Filing Date) 35, United States Code, § 120 of any United States application into of this application is not disclosed in the prior United States 35, United States Code, § 112, I acknowledge the duty to Regulations, § 1.56 which became available between the filing g date of this application.	PCT Application Entering National Phase PCT International Application No. [App. No.] and was amended on and understand the contents of the above-identified specification, to above. formation which is material to patentability as defined in Title 37, Coolins under Title 35, United States Code, § 119(a)-(d) of any foreign at have also identified below any foreign application for patent or inverse on on which priority is claimed. [Day/Month/Year Filed] 35, United States Code, § 119(e) of any United States provisional application of this application is not disclosed in the prior United States at the 35, United States Code, § 112, I acknowledge the duty to disclose Regulations, § 1.56 which became available between the filing date of a grant date of this application.	PCT Application Entering National Phase PCT International Application No. [App. No.] and was amended on [Date of Amel and understand the contents of the above-identified specification, including the to above. formation which is material to patentability as defined in Title 37, Code of Federal fits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) thave also identified below any foreign application for patent or inventor's certific on on which priority is claimed. Priority Claim Tyes Output (Day/Month/Year Filed) 35, United States Code, § 119(e) of any United States application(s) listed below any inns of this application is not disclosed in the prior United States application in Regulations, § 1.56 which became available between the filing date of the prior application.		

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Frederick H. Colen, Reg. N . 28,061; W. Scott Railton, Reg. No. 23,039; Gene A. Tabachnick, Reg. No. 33,801; Paul D. Bangor, Jr., Reg. No. 34,768; Maria N. Rullo, Reg. No. 37,433; Kirsten R. Rydstrom; Reg. No. 38,603; Barry J. Coyne Reg. No. 43,566; Cheryl L. Gastineau, Reg. No. 39,469, Ian K. Samways, Reg. No. 36,664; Charles H. Dougherty, Jr., Reg. No. 42,494; Robert D. Kucler, Reg. No. 45,908; Louis M. Heidelberger, Reg. No. 27,899; John W. Goldschmidt, Jr., Reg. No. 34,828; Daniel H. Golub, Reg. No. 33,701; William J. McNichol, Jr., Reg. No. 31,179; R. Anthony Diehl, Reg. No. 38,432; Marc J. Farrell, Reg. No. 37,826; Thomas J. McWilliams, Reg. No. 44,930; Matthew J. Esserman, Reg. No. 41,536; Maryellen Feehery, Reg. No. P-44,677; Alison B. Weisberg, Reg. No. P-45,206; Nanda Kumar, Reg. No. P-44,853; Mary E. Buckles, Reg. No. 31,907; Juan C. Marquez, Reg. No. 34,072; Stanley P. Fisher, Reg. No. 24,344 and Terri J. Latonik, Reg. No. 36,577.

Address all telephone calls to Mary-Elizabeth Buckles at telephone number (202) 414-9267

Address all correspondence to:

Mary-Elizabeth Buckles

REED SMITH SHAW & MCCLAY LLP

1301 K Street, N.W. Suite 1100-East Tower Washington, DC 20005-3317

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 100 V of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventor's Signature

Full name of sole or first inventor

Residence Citizenship

Post Office Address

Manuel J. Villa

North Wood Apartments

700 Warren Road, Apt. 11-3F, Ithaca, NY 14850 USA

Date: 10/3/00

Mexico

North Wood Apartments, 700 Warren Road, Apt. 11-3F, Ithaca, NY 14850 USA

Inventor's Signature

Full name of second inventor

Residence Citizenship

Post Office Address

Susan A. Henry

91 Ellis Hollow Creek Road, Ithaca, NY 14850 USA

United States of America

91 Ellis Hollow Creek Road, Ithaca, NY 14850 USA

REED SMITH SHAW & MCCLAY LLP

1301 K Street, N.W., Suite 1100-East Tower Washington, DC 20005-3317 Ph: 202-414-9200

-2-

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Manuel J. Villa, et. al. Serial No.: (Not yet assigned)		CELLS ENGINEERED TO CONTAIN GENES OF INTEREST WITHOUT DRUG RESISTANCE GENE MARKERS AND MATERIALS AND							
					Filed: (Not ye	et assigned)	METHODS THEREFOR		
VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) and 1.27(d)) - Nonprofit Organization									
	I hereby declare that I am an official emp	owered to act on behalf of the nonprofit organization							
identified below	r:								
Name Of Or	GANIZATION: Carnegie Mellon Uni	versity							
ADDRESS OF ORGANIZATION: 5000 Forbes Avenue, Warner Hall, 4th Floor, Pittsburgh, PA 15213									
\boxtimes	University Or Other Institution	NIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION							
	TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3))								
	NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF								
STATE OF THE UNITED STATES OF AMERICA									
(NAME OF STATE: [State])									
	(CITATION OF STATUTE: [Cite])								
	WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3)) IF LOCATED IN THE UNITED STATES OF AMERICA								
	•	ENTIFIC OR EDUCATIONAL UNDER STATUTE F AMERICA IF LOCATED IN THE UNITED							
	(NAME OF STATE: [State])								

(CITATION OF STATUTE: [Cite])

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code with regard to the invention entitled CELLS ENGINEERED TO CONTAIN GENES OF INTEREST WITHOUT DRUG RESISTANCE GENE MARKERS AND MATERIALS AND METHODS THEREFOR by inventors Manuel J. Villa and Susan A. Henry described in the specification filed herewith Application Serial No. [No.], filed [Date]. Patent No. [No.], issued [Date]. I hereby declare that the rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention. If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e). *NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities (37 CFR 1.27) NAME: ADDRESS: ☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION NAME: ADDRESS: ☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION NAME: ADDRESS: INDIVIDUAL SMALL BUSINESS CONCERN NONPROFIT ORGANIZATION I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue

resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issu fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING:

Susan Burkett

TITLE IN ORGANIZATION:

Associate Provost

ADDRESS OF PERSON SIGNING:

Carnegie Mellon University

5000 Forbes Avenue, Warner Hall, 4th Floor, Pittsburgh, PA 15213

SIGNÁTURE